Finerenone in Persons with Chronic Kidney Disease without Diabetes

Hiddo J.L. Heerspink

George Institute for Global Health, University of New South Wales, Sydney

Brendon L. Neuen

George Institute for Global Health, University of New South Wales, Sydney

Rajiv Agarwal

Division of Nephrology, Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis

David Z.I. Cherney

Division of Nephrology, University Health Network, Toronto General Hospital, University of Toronto, Toronto

Carolyn S.P. Lam

National Heart Centre Singapore, Singapore

Katherine R. Tuttle

Providence Inland Northwest Health, University of Washington School of Medicine, Spokane

Christoph Wanner

Pantelis Sarafidis

Niels Jongs

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

J. David Smeijer

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

Meike Brinker

Cardiology and Nephrology Clinical Development, Bayer, Wuppertal, Germany

Nicole Rethemeier

Clinical Statistics and Analytics, Bayer, Wuppertal, Germany

Patrick Schloemer

Clinical Statistics and Analytics, Bayer, Berlin

Paula Vesterinen

Medical and Scientific Affairs, Bayer, Espoo, Finland

David Goldsbury

Bayer, Reading, United Kingdom

Sara Dizayee

Regulatory Strategy Cardiology and Nephrology, Bayer, Wuppertal, Germany

Jon W. Mares

Bayer US Medical Affairs, Whippany, NJ

Vlado Perkovic

University of New South Wales, Sydney